Bio-Rad Reports First-Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bio-Rad Reports First-Quarter 2015 Financial Results

HERCULES, CA--(Marketwired - May 5, 2015) - Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and ( NYSE : BIO.B ), a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2015.

First-quarter reported revenues were $472.8 million, down 7.2% compared to $509.3 million reported for the first quarter of 2014. On a currency-neutral basis, quarterly revenues increased 1.4% compared to the same period last year. First-quarter 2015 gross margin was 57.1% compared to 54.0% during the same quarter last year. The year-over-year increase in gross margin in the first quarter was the result of favorable sales mix and improved manufacturing variances in the first quarter of 2015, as well as benefits from the consolidation and closure of certain facilities during 2014.

Net income for the first quarter of 2015 was $17.8 million, or $0.61 per share on a fully diluted basis compared to $6.7 million or $0.23 per share during the same period last year. In addition to gross margin gains, the year-over-year increase in net income was also helped by the absence of a nonrecurring expense accrued in the first quarter of 2014. 

The effective income tax rate for the first quarter of 2015 was 33% compared to the tax rate for the first quarter of 2014 of 54%. The higher tax rate in 2014 was primarily due to higher unbenefitted losses in foreign jurisdictions relative to lower pretax income. 

"Currency headwinds mask what was otherwise a respectable performance in the first quarter this year," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "With the completion of our new more globalized management structure, we look forward to improvements in operational efficiency." 

Life Science The Life Science segment net sales for the first quarter of 2015 were $155.9 million, down 3.4% compared to the same period last year. On a currency-neutral basis, Life Science segment sales increased 4.0% compared to the first quarter in 2014. Results from the first quarter benefitted from increased sales of our Droplet Digital ™ PCR, process media, and cell biology products. The currency-neutral sales increase, which reflected strength primarily in North American and European markets, was somewhat offset by slower sales in Asia.

Clinical Diagnostics Net sales for the Clinical Diagnostics segment in the first quarter of 2015 were $313.6 million, down 8.9% compared to the first quarter for 2014. On a currency-neutral basis, net sales increased 0.2% compared to the same period last year. Performance of the Clinical Diagnostics segment in the first quarter benefitted from sales of quality control and immunology products. While sales increased in North America, Eastern Europe, and China in the first quarter of 2015, sales in European markets continue to experience consolidation and pricing pressures. 

Management will discuss these results in a conference call at 2 PM Pacific Daylight Time (5 PM Eastern Daylight Time) May 5, 2015. Interested parties may access the call at 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., passcode: 21291896.

You may also listen to the conference call live via a webcast that is available on the "Investor Relations" section of our website under "Quarterly Results" at www.bio-rad.com .

The webcast will be available for up to a year. 

About Bio-Rad Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and ( NYSE : BIO.B ) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com .

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our improved operational efficiency and future financial performance. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include recent changes to our global organizational structure and executive management team, difficulties in implementing our global enterprise resource planning system, our ability to develop and market new or improved products according to our business plan, our ability to compete effectively, product quality and liability issues, supply chain issues, reductions in government funding or capital spending of our customers, changes in the healthcare industry, international legal and regulatory risks, foreign currency exchange fluctuations, global economic conditions, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2015 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

   
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Income  
             
(in thousands, except per share data)  
(UNAUDITED)  
             
             
    Three Months Ended March 31,  
    2015     2014  
Net sales   $ 472,821     $ 509,344  
  Cost of goods sold     202,715       234,055  
Gross profit     270,106       275,289  
                 
  Selling, general and administrative expense     188,555       202,275  
  Research and development expense     47,202       52,543  
Income from operations     34,349       20,471  
                 
  Interest expense     5,002       3,857  
  Foreign currency exchange losses, net     3,806       2,737  
  Other (income) expense, net     (1,153 )     (661 )
Income before income taxes     26,694       14,538  
                 
  Provision for income taxes     (8,876 )     (7,870 )
                 
Net income   $ 17,818     $ 6,668  
                 
Basic earnings per share:                
  Net income per basic share   $ 0.61     $ 0.23  
                 
  Weighted average common shares - basic     29,092       28,791  
                 
Diluted earnings per share:                
  Net income per diluted share   $ 0.61     $ 0.23  
                 
  Weighted average common shares - diluted     29,289       29,059  
                 
 
 
 
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
 
(In thousands)
 
         
    March 31,   December 31,
    2015   2014
    (UNAUDITED)    
Current assets:        
  Cash and cash equivalents   $ 425,728   $ 413,251
  Short-term investments     284,958     284,384
  Accounts receivable, net     342,223     377,640
  Inventories, net     478,375     470,997
  Other current assets     170,560     170,095
    Total current assets     1,701,844     1,716,367
             
Property, plant and equipment, net     428,300     428,836
Goodwill, net     503,422     500,441
Purchased intangibles, net     242,970     254,228
Other investments     400,262     389,309
Other assets     49,398     52,097
    Total assets   $ 3,326,196   $ 3,341,278
             
Current liabilities:            
  Accounts payable, accrued payroll and employee benefits   $ 250,813   $ 282,034
  Current maturities of long-term debt     264     265
  Income and other taxes payable     31,926     35,165
  Other current liabilities     133,879     129,297
    Total current liabilities     416,882     446,761
             
Long-term debt, net of current maturities     435,661     435,710
Other long-term liabilities     275,140     273,652
    Total liabilities     1,127,683     1,156,123
             
    Total stockholders' equity     2,198,513     2,185,155
    Total liabilities and stockholders' equity   $ 3,326,196   $ 3,341,278
             
             
             
             
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Cash Flows  
   
(In thousands)  
(UNAUDITED)  
             
             
    Three Months Ended March 31,  
             
    2015     2014  
             
Cash flows from operating activities:            
  Cash received from customers   $ 478,479     $ 544,447  
  Cash paid to suppliers and employees     (453,986 )     (471,452 )
  Interest received (paid), net     471       (292 )
  Income tax refunds (payments)     1,503       (6,909 )
  Other operating activities     2,979       (224 )
  Net cash provided by operating activities     29,446       65,570  
                 
Cash flows from investing activities:                
  Payments for purchases of long-term investments     (895 )     (1,364 )
  Other investing activities     (27,096 )     (34,206 )
  Net cash used in investing activities     (27,991 )     (35,570 )
                 
Cash flows from financing activities:                
  Payments on long-term borrowings     (66 )     (66 )
  Other financing activities     (265 )     3,556  
  Net cash (used in) provided by financing activities     (331 )     3,490  
                 
Effect of foreign exchange rate changes on cash     11,353       (534 )
                 
Net increase in cash and cash equivalents     12,477       32,956  
Cash and cash equivalents at beginning of period     413,251       331,551  
Cash and cash equivalents at end of period   $ 425,728     $ 364,507  
                 
                 
Reconciliation of net income to net cash provided by operating activities:                
Net income   $ 17,818     $ 6,668  
Adjustments to reconcile net income to net cash provided by operating activities:                
    Depreciation and amortization     32,283       36,671  
    Changes in working capital     (20,619 )     22,338  
    Other     (36 )     (107 )
Net cash provided by operating activities   $ 29,446     $ 65,570  
                 

Investor and Financial Contacts: Bio-Rad Laboratories, Inc. Christine Tsingos Executive Vice President and Chief Financial Officer Ron Hutton Vice President, Treasurer 510-724-7000 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Insiders Buy Up on MicroStrategy While Analysts Expect Growth

Updated Category News Views 198

Insider Purchases Indicate Confidence in MicroStrategy Recently, insiders at MicroStrategy Incorporated (NASDAQ: MSTR) have made notable stock purchases that are turning heads in the financial community. Even though there were increases in insider share sales in the last quarter, which reached a two-year peak, the market has not reacted unfavorably. Most of these sales...

Continue Reading
Burlington Stores Insider Transaction: Stephen Ferroni's Move

Updated Category News Views 174

Burlington Stores Insider Transaction Details In a significant move recently disclosed in an SEC filing, Stephen Ferroni, the Senior Vice President at Burlington Stores, made headlines by exercising company stock options. This transaction, involving the exercise of options for 1,123 shares, amounted to a transaction value of approximately $200,331. The filing highlights...

Continue Reading
Clairvest Group's Strategic Acquisition of MGM Northfield Park

Updated Category News Views 371

Clairvest Group Expands Horizons with MGM Northfield Park Acquisition Exciting developments are shaping the landscape for Clairvest Group Inc. as they embark on a significant acquisition journey with MGM Northfield Park. This strategic move not only highlights Clairvest's commitment to growth in the gaming sector but also enhances their longstanding reputation for...

Continue Reading
Innovent Biologics Showcases Promising Research at ADA 85th Sessions

Updated Category News Views 576

Innovent Biologics Presents Cutting-Edge Research at ADA Innovent Biologics, Inc. (HKEX: 01801) has made significant advancements in the biopharmaceutical industry, focusing on innovative treatments for oncology, autoimmune diseases, and metabolic conditions. Recently, the company announced that it will showcase exciting results from its research pipeline at the American...

Continue Reading
Promising Results from HERIZON-GEA-01 Trial Support Ziihera®

Updated Category News Views 288

Encouraging HERIZON-GEA-01 Phase 3 Findings Reinforce Ziihera®’s Role Ziihera, when combined with chemotherapy, has demonstrated a significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy combinations. It also showed a strong trend towards enhancing overall survival (OS) at the first analysis. Clinical Outcomes of Ziihera in...

Continue Reading